Leukemia 2014 Sep 02
Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment.
Related Questions
For example, if the patient was on dasatinib before relapse, would you consider other second generation or third generation TKIs?
New answer by at CHU Sainte-Justine (September 5, 2020)
Mechanisms of resistance in Ph-like ALL have not been extensively studied and will definitively be an active area of research. Given the biological similarities between Ph+ AL...